The FDA has granted accelerated approval to sevabertinib (Hyrnuo), for previously treated HER+ metastatic non-squamous ...
The FDA has approved epcoritamab-bysp (Epkinly) with rituximab and lenalidomide for relapsed or refractory follicular ...
Novartis has opened a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California, ...
The FDA has approved ziftomenib (KOMZIFTI), the first oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). In the KOMET-001 trial, the therapy ...
EMA’s CHMP Backs Subcutaneous Pembrolizumab in Head and Neck Cancer ...
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted two positive opinions for Merck’s anti–PD-1 therapy pembrolizumab (KEYTRUDA®), potentially expanding ...
The Phase III SUNMO trial could mark a breakthrough for transplant-ineligible patients with relapsed or refractory large B-cell lymphoma. In this ONCOLife interview, we spoke with Dr. Jason Westin, ...
Findings from the DYNAMIC-III trial, show that circulating tumor DNA (ctDNA) testing can transform post-surgical care in Stage III colon cancer. Among more than 1,000 patients, ctDNA-negative ...
AnX Robotica announced that its AI-assisted tool for small bowel capsule endoscopy has received FDA clearance. With this approval, NaviCam ProScan becomes the first AI-assisted tool in its field. It ...
The first patient has been enrolled in PROPEL, a multicenter registry evaluating Aliya® pulsed electric field (PEF) ablation for soft-tissue lesions in the lung, liver, and other organs. This ...
Vividion Therapeutics and Bayer are advancing VVD-214, the world’s only clinical-stage covalent WRN inhibitor, for MSI-high cancers including colorectal, endometrial, ovarian, and gastric tumors.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback